Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 15/20 | 0.53 |
| ▸ | OXTR | P30559 | 12/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5155982 | 0.88 | AVPR1A (0.56) | AVPR1AOXTR | |
| SCHEMBL5152897 | 0.85 | OXTR (0.69) | AVPR1AOXTRTRPA1TRPM8 | |
| SCHEMBL5155822 | 0.85 | AVPR1A (0.39) | AVPR1AOXTRCYP2C9CYP2C19EPHX2 | |
| SCHEMBL5157264 | 0.84 | OXTR (0.55) | AVPR1AOXTRCYP2C9CYP2C19EPHX2 | |
| SCHEMBL5157145 | 0.81 | AVPR1A (0.40) | AVPR1AOXTRCYP2C9CYP2C19EPHX2 | |
| SCHEMBL5426182 | 0.80 | AVPR1A (0.54) | AVPR1AOXTRTRPA1TRPM8 | |
| SCHEMBL5428048 | 0.80 | AVPR1A (0.52) | AVPR1AOXTREPHX2TRPA1TRPM8 | |
| SCHEMBL5424649 | 0.78 | OXTR (0.45) | AVPR1AOXTRTRPA1TRPM8 | |
| SCHEMBL5155966 | 0.78 | AVPR1A (0.48) | AVPR1AOXTRTRPA1TRPM8 | |
| SCHEMBL8256810 | 0.78 | AVPR1A (0.48) | AVPR1AOXTRTRPA1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225333-A1 | 3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor | BRYANS JUSTIN S | 2007-09-27 | — | — | US | disclosed |
| US-20070225333-A1 | 3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor | BRYANS JUSTIN S | 2007-09-27 | — | — | US | disclosed |
| US-20070225333-A1 | 3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor | BRYANS JUSTIN S | 2007-09-27 | — | — | US | disclosed |
| WO-2005105779-A1 | 3-HETEROCYCLYL-4-PHENYL-TRIAZOLE DERIVATIVES AS INHIBITORS OF THE VASOPRESSIN V1A RECEPTOR | PFIZER LIMITED (GB) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225333-A1 | 3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor | AVPR2, RXFP3, AVPR1A | AVPR1A 3/4885OXTR 9/4885CYP2C9 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.